Sleep advances : a journal of the Sleep Research Society
January 1, 2023
David A Kalmbach, Philip Cheng, Anthony N Reffi et al.
16 citations
A mindfulness-based sleep program for pregnant women with insomnia appears to work by reducing nighttime cognitive arousal and the effort invested in trying to sleep. In a small trial of 12 pregnant women with insomnia disorder, 75% reported high cognitive arousal before treatment, dropping to 8.3% after treatment. All women whose insomnia remitted had low cognitive arousal afterward, while half of non-remitters still had high arousal. Lower cognitive arousal and less sleep effort predicted same-week improvements in insomnia and later reductions in depression. The findings suggest that quieting a racing mind and decreasing sleep effort are key mechanisms through which mindfulness-based insomnia therapy alleviates both insomnia and depression during pregnancy.
Sleep Medicine
August 1, 2023
David A Kalmbach, Philip Cheng, Anthony N Reffi et al.
15 citations
A proof-of-concept trial of a treatment combining mindfulness with behavioral sleep strategies (PUMAS) for pregnant women with insomnia found large reductions in insomnia, depression, and cognitive arousal. Among 12 participants with insomnia disorder (five also had depression), 83.3% achieved insomnia remission after six telemedicine sessions. All five depressed patients remitted from depression. Nocturnal cognitive arousal, perinatal-focused rumination, and sleep effort all showed large improvements. Patients rated sleep restriction and guided meditations as most helpful and were highly satisfied with the telemedicine format and meditation app.
Journal of Sleep Research
February 1, 2024
David A Kalmbach, Anthony N Reffi, Jason C Ong et al.
9 citations
A mindfulness sleep program for pregnant women with insomnia, combining behavioral sleep strategies and meditation, led to large increases in everyday mindfulness and medium-large increases in maternal-fetal attachment. Participants also reported large reductions in anxiety, repetitive thinking, insomnia-focused rumination, and sleep-related daytime impairment. These preliminary results from a small trial of 11 women suggest that such a program may benefit multiple aspects of maternal wellbeing beyond sleep and depressed mood.
Sleep
May 1, 2025
Michael J. Thorpy, Jennifer M Mundt, Sally Ibrahim et al.
In people with narcolepsy type 1, once-nightly sodium oxybate reduced the number of hypnagogic/hypnopompic hallucinations (HH) per day compared with placebo over 13 weeks. At baseline, participants averaged about 0.6 HH events per day. By week 13, the sodium oxybate group showed a mean reduction of 0.29 events per day, while the placebo group showed a reduction of 0.24 events per day. Among 12,455 total HH events, 62% were hypnagogic (occurring at sleep onset) and 38% were hypnopompic (occurring upon waking). The most common hallucination types were feeling that shadows or objects are moving or distorting and feeling another presence in the room. Approximately half as many events of feeling attacked, flying, or falling into a hole were reported with sodium oxybate versus placebo.
The International Journal of Aging and Human Development
May 1, 1975
Milton Kramer, Thomas Roth, John Trinder
Among chronic brain syndrome patients, dream recall rates differ by severity of organic impairment and age. Mildly organic patients recalled 57% of dreams, severely organic middle-aged patients recalled 35%, and aged severely organic patients recalled only 8%. The difference between mild and severe middle-aged groups was not statistically significant, but the aged severely organic group's recall was significantly lower than either middle-aged group. Dream content also differed between mild and severe middle-aged groups and between all patients and normal young men.